Chargement en cours...
Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
OBJECTIVES: Biosimilar infliximab, the first similar biological medicinal product containing monoclonal antibodies to be commercialised, is likely to contribute to a significant reduction in healthcare costs. We aimed to assess the cost savings potential over 1 year of the use of biosimilar inflixim...
Enregistré dans:
| Publié dans: | Eur J Hosp Pharm |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6451627/ https://ncbi.nlm.nih.gov/pubmed/31156910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2016-000904 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|